首页> 外文OA文献 >>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

【2h】

>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

机译：>患者的人口统计学和临床特征，处方先驱转化酶枯草杆菌素/ kexin型9型抑制剂治疗和当前脂质降低治疗的患者进行了修饰

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Seth J Baum; Rolin L Wade; Pin Xiang; Jorge Arellano; Cesar Cerezo Olmos; Sasikiran Nunna; Chi-Chang Chen; Cathryn M Carter; Nihar R Desai;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified [J] . Seth J Baum, Rolin L Wade, Pin Xiang, Therapeutics and Clinical Risk Management . 2019,第4期

机译：患者的人口统计学和临床特征，处方先驱转化酶枯草杆菌蛋白酶素/ kexin型9型抑制剂治疗及其当前脂质降低治疗的患者进行了修饰
2. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 Trial [J] . DesaiN.R., KohliP., GiuglianoR.P., Circulation: An Official Journal of the American Heart Association . 2013,第9期

机译：AMG145，一种针对9型前蛋白转化酶枯草杆菌素kexin的单克隆抗体，可显着减少接受他汀类药物治疗的高胆固醇血症患者的脂蛋白（a）：对LDL-C评估，对9种前蛋白转化酶枯草杆菌素kexin单克隆抗体联合他汀类药物疗法的抑制作用（LAPLACE ）溶栓在心肌梗死（TIMI）57中的试验
3. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing [J] . Hess Gregory P., Natarajan Pradeep, Faridi Kamil F., Circulation: An Official Journal of the American Heart Association . 2017,第23期

机译：ProProtein转化酶枯草杆菌蛋白酶/ kexin型9型抑制剂治疗付款人批准和拒绝，以及成功规定的患者特征
4. Clinical Presentation, Outcome and Therapy in Patients with Acute Myocardial Infarction. Correlation with Demographic Factors -A RO-STEMI Analysis Report [C] . D. Tint, M. RSdoi, Gh. Pamfil, International Congress on Coronary Artery Disease . 2007

机译：急性心肌梗死患者的临床介绍，结果和治疗。与人口统计因子的相关性-a ro-steni分析报告
5. Evaluation of the Interaction Between Proprotein Convertase Subtilisin/Kexin Type 9 and Sterol Carrier Protein-2 [D] . Ahranjani, Reza. 2017

机译：评价前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型与甾醇载体蛋白2的相互作用。
6. Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified [O] . Seth J Baum, Rolin L Wade, Pin Xiang, 2019

机译：处方前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型抑制剂治疗的患者的人口统计学特征和临床特征以及目前使用降脂治疗的患者
7. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy [O] . Constantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, 2017

机译：靶向前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（pCsK9）的降脂干预：降脂治疗的新篇章

>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

著录项

引文网络

相似文献

相关主题

期刊订阅